Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q1 2023 Earnings Presentation

18 slides from Abcellera Biologics's earnings presentation, May 4, 2023

  1. Slide 1: Q1 2023 Business Update

    Q1 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA MAY 4, 2023

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation contains forward-looking statements, including These statements involve risks, uncertainties and other factors that may statements made pursuant to the safe harbor provisions of the Private cause actual results, levels of activity, performance, or achievements to be Q1 2

  3. Slide 3: Q1 2023 Business Update Summary

    Q 1 2 0 2 3 . B U S I N E S S U P D AT E S U M M A R Y. Q1 2023 BUSINESS UPDATE BUILDING THE INDUSTRY’S $821M in total cash, cash equivalents & marketable securities ENGINE FOR 177 cumulative programs under contract ANTIBODY 101 cumulative partnered programs started THERAPEUTICS 9 COPYRIGHT © ABCELL

  4. Slide 4: All programs leverage partnerships

    All programs leverage partnerships. PARTNER-INITIATED PROGRAMS TECHNOLOGY DEVELOPMENT Q1 2023 BUSINESS UPDATE Discovery Co-Development Pre-Partnered Programs Programs Programs COPYRIGHT © ABCELLERA 4

  5. Slide 5: T-Cell Engager Platform: Solving key challenges in cancer treatments

    T E C H N O L O G Y D E V E L O P M E N T. T - C e l l E n g a g e r P l a t f o r m Solving key challenges in T-cell engagers (TCEs) are antibodies with 2 arms developing T-cell engager that are designed to simultaneously bind to cancer cells and specific immune cells called T cells. TCEs cancer tr

  6. Slide 6: Create T-cell engagers with optimal properties, fast

    T E C H N O L O G Y D E V E L O P M E N T. T - C e l l E n g a g e r P l a t f o r m Create T-cell engagers with optimal properties, fast. Q1 2023 BUSINESS UPDATE K E Y H I G H L I G H TS Fine-tune tumor cell killing and cytokine release using COPYRIGHT © ABCELLERA TCEs that are superior to commonly

  7. Slide 7: Unlock high-value, difficult cancer targets

    T E C H N O L O G Y D E V E L O P M E N T. T - C e l l E n g a g e r P l a t f o r m Unlock high-value, difficult cancer targets. Q1 2023 BUSINESS UPDATE K E Y H I G H L I G H TS Find ultra specific antibodies that are COPYRIGHT © ABCELLERA comparable or superior to clinical benchmarks 7

  8. Slide 8: One partner program against difficult target advances to the clinic

    PA R T N E R - I N I T I AT E D P R O G R A M S . One partner program against difficult target Q1 2023 BUSINESS UPDATE advances to the clinic. One molecule entered the clinic COPYRIGHT © ABCELLERA 8

  9. Slide 9: Helping partners reach their next value inflection point

    PA R T N E R - I N I T I AT E D P R O G R A M S . Helping partners reach their next value inflection point. Q1 2023 BUSINESS UPDATE AbCellera was a founding partner in Abdera, who just announced $142M in financing. First program started in March 2021, and Abdera announced it plans to file an IND in

  10. Slide 10: Capital allocation to maximize long-term value while minimizing risk

    Capital allocation to maximize long-term value Q1 2023 BUSINESS UPDATE while minimizing risk. Forward integration Develop technology Build the portfolio to expand the capabilities to unlock new target by advancing high- of our engine, including classes and modalities, quality programs manufacturing,

  11. Slide 11: Q1 2023 Financials Update

    Q1 2023 COPYRIGHT © ABCELLERA FINANCIALS UPDATE

  12. Slide 12: Strong portfolio growth

    FINANCIALS Strong portfolio growth. Cumulative # of Cumulative # of Partnered Program Starts Molecules in the Clinic Q1 2023 BUSINESS UPDATE 101 9 110 9 100 8 Total # of 90 7 80 Programs Under Contract 6 177 70 60 5 50 4 Total # of 40 3 30 Discovery Partners 41 20 2 10 1 0 0 2015 2016 2017 2018 2019

  13. Slide 13: Now molecules in the clinic

    FINANCIALS Now 9 molecules in the clinic. MOLECULE STAGE THERAPEUTIC AREA PARTNER PROGRAM TYPE bamlanivimab Marketed, Emergency Use • infectious disease: COVID- (LY-CoV555) Authorization (EUA) 19 AbCellera pre-partnered program PARTNERED bebtelovimab Marketed, Emergency Use • infectious disease: (LY

  14. Slide 14: $12M total revenue, driven by research fees

    FINANCIALS $12M total revenue, driven by research fees from robust discovery activity. Revenue USD $316.6M ROYALTIES Q1 2023 BUSINESS UPDATE MILESTONES LICENSING RESEARCH FEES $12.2M $1.3M $10.6M COPYRIGHT © ABCELLERA Q1 2022 Q1 2023 14

  15. Slide 15: Operating expenses reflect ongoing investments

    FINANCIALS Operating expenses reflect ongoing investments. Operating Expenses USD RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN Q1 2023 BUSINESS UPDATE +$26.3M $52.6M $26.4M +$0.9M +$1.4M $14.3M $15.1M COPYRIGHT © ABCELLERA $2.4M $3.8M Q1 2022 Q1 2023 Q1 2022 Q1 2023 Q1 2022 Q1 2023 15

  16. Slide 16: Net loss of $40M; ($0.14) per share

    FINANCIALS Net loss of $40M; equivalent to ($0.14) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC EARNINGS PER SHARE: DILUTED Q1 2023 BUSINESS UPDATE $168.6M $0.59 $0.54 -$40.1M -$0.14 -$0.14 COPYRIGHT © ABCELLERA Q1 2022 Q1 2023 Q1 2022 Q1 2023 Q1 2022 Q1 2023 16

  17. Slide 17: Total cash, equivalents, and marketable securities

    FINANCIALS Over 800 million in total cash, equivalents, and marketable securities. Cash Flows USD $915M $824M Q1 2023 BUSINESS UPDATE $500M Marketable Securities $603M Marketable Securities $98M ($44M) Marketable Securities (net) $387M $51M Cash & Other Equivalents ($150M) $0M $0M $193M Cash & Equiv

  18. Slide 18: Thank You

    COPYRIGHT © ABCELLERA 18 Q1 2023 BUSINESS UPDATE THANK YOU

AbCellera Biologics — Q1 2023 Earnings Presentation on 6ix